Stay updated with breaking news from Viral Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims
Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vacci...
A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States.
Program employs a coordinated approach and serves as a template for response against rapidly evolving pandemic pathogens
SARS-CoV-2, the virus that spreads COVID-19, caused a pandemic that killed more than five million people worldwide. Several variants of SARS-CoV-2 have emerged during the pandemic, drawing attention to how new mutations impact virus replication, infectivity, transmission, and immunity.